SCHEMBL4172913

SCHEMBL4172913

Cc1ccc(C(=O)N2CCC(c3ccc(CNS(=O)(=O)CC(=O)O)cc3)CC2)cc1NS(C)(=O)=O

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FASN P49327 13/20 0.51
HPGD P15428 3/20 0.47
ALDH1A1 P00352 3/20 0.47
LMNA P02545 2/20 0.47
MEN1 O00255 1/20 0.47
CYP3A4 P08684 1/20 0.47
GAA P10253 1/20 0.47
CYP2C19 P33261 1/20 0.47
HTT P42858 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
OPRM1 P35372 1/20 0.42
OPRK1 P41145 1/20 0.42
GLA P06280 1/20 0.41
MAPT P10636 1/20 0.41
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4187313 0.92 FASN (0.53) FASNHPGDALDH1A1LMNAMEN1
SCHEMBL4175563 0.91 FASN (0.49) FASNHPGDALDH1A1LMNAMEN1
SCHEMBL4176863 0.91 FASN (0.55) FASNHPGDALDH1A1LMNAMEN1
SCHEMBL4180483 0.90 FASN (0.51) FASNHPGDALDH1A1LMNAMEN1
SCHEMBL4181728 0.89 FASN (0.50) FASNHPGDALDH1A1LMNAMEN1
SCHEMBL4190006 0.87 FASN (0.55) FASNHPGDALDH1A1LMNAMEN1
SCHEMBL4180038 0.87 FASN (0.51) FASNHPGDALDH1A1LMNAMEN1
SCHEMBL4175605 0.86 FASN (0.56) FASN
SCHEMBL4172482 0.86 FASN (0.52) FASNHPGDALDH1A1LMNAMEN1
SCHEMBL4182773 0.85 FASN (0.54) FASNHPGDALDH1A1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105305-A1 Therapeutic Agents - 550 ASTRAZENECA AB (SE) 2009-04-23 US disclosed
WO-2008075070-A1 SULFONAMIDE DERIVATIVES FOR THERAPEUTIC USE AS FATTY ACID SYNTHASE INHIBITORS ASTRAZENECA AB (SE) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105305-A1 Therapeutic Agents - 550 FABP4, GPR119, FASN FASN 3/4885HPGD 783/4885ALDH1A1 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.